Healthcare innovation is often associated with breakthrough medicines, advanced diagnostics and cutting-edge medical devices. Yet one of the most significant developments in recent years has emerged through software. Digital therapeutics, often referred to as DTx, are increasingly transforming the way certain diseases and conditions are prevented, managed and treated, offering patients evidence-based interventions delivered through digital platforms.

Different to general wellness apps

Unlike general wellness apps, digital therapeutics are designed to deliver clinical outcomes. They are often backed by rigorous research and can be prescribed or recommended as part of a broader treatment plan. From supporting people with diabetes and cardiovascular disease to helping manage insomnia, anxiety and substance use disorders, these technologies are opening new possibilities for personalised care.

Reflection of a wider shift in healthcare

The rise of digital therapeutics reflects a wider shift in healthcare towards prevention and patient empowerment. Rather than relying solely on in-person interventions or pharmaceuticals, DTx tools can provide ongoing support through smartphones, wearables and connected devices. They can offer behavioural coaching, monitor symptoms in real time and adapt interventions according to patient progress.

Significant in chronic disease management

This is particularly significant in chronic disease management, where long-term behaviour change can be critical to improving outcomes. Digital therapeutics can help patients maintain treatment adherence, track lifestyle factors and receive feedback outside traditional clinical environments. In doing so, they may reduce pressures on healthcare services while improving patient engagement.

Interest could be accelerated even further

Interest in the field has accelerated globally. Analysts at McKinsey have suggested digital therapeutics could become a major component of future healthcare delivery, particularly as systems seek scalable ways to manage rising demand. Meanwhile, regulatory pathways are beginning to mature, helping create clearer routes for validated technologies to reach patients.

The potential has also attracted support from policymakers and health leaders. Dr Jesse Ehrenfeld, President of the American Medical Association, has said: “Digital health tools have the potential to empower patients and improve care, but they must be clinically validated and integrated thoughtfully.” That emphasis on evidence and integration remains central to the sector’s development.

Ket areas include mental health

Mental health has become one of the most prominent areas for digital therapeutics innovation. Programmes based on cognitive behavioural therapy can now be delivered digitally to support people with anxiety, depression or insomnia. For some patients, these interventions can increase access to support, particularly where traditional services face long waiting times.

Beyond mental health, digital therapeutics are being explored in respiratory care, neurological conditions and rehabilitation. Some platforms support stroke recovery through guided exercises, while others use software-based interventions to support patients living with chronic pain. The flexibility of these approaches has encouraged growing interest from clinicians and researchers alike.

AI has a key role

Artificial intelligence is also beginning to shape the next phase of digital therapeutics. AI-driven tools may allow interventions to become even more personalised, adjusting recommendations based on user behaviour or physiological data. Combined with remote monitoring, this could contribute to more responsive and preventative models of care.

However, challenges remain. Questions around regulation, reimbursement and digital inclusion continue to shape discussion around the sector’s future. Ensuring patients can access and trust these technologies will be just as important as technological advancement itself. There is also continued focus on protecting patient data and demonstrating long-term clinical effectiveness.

Industry leaders argue collaboration will be key to addressing these issues. Jennifer Goldsack, Chief Executive of the Digital Medicine Society, has said: “Evidence is the foundation for digital medicine and digital therapeutics to achieve their promise.” That principle underpins efforts to move beyond innovation for its own sake and towards meaningful impact in healthcare systems.

As healthcare increasingly embraces digital transformation, digital therapeutics represent a compelling example of software moving from support tool to treatment option. Their growth signals not simply a technological trend but a broader evolution in how care may be delivered in the years ahead.

For life sciences and health technology sectors, this emerging field offers both opportunity and responsibility. If supported by robust evidence, thoughtful regulation and equitable access, digital therapeutics could play a growing role in shaping more connected, personalised and preventative healthcare.